Related Experiment Video

Updated: Sep 3, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD

Hina Qayoom1, Umar Mehraj1, Shazia Sofi1

  • 1Department of Bioresources, School of Biological Sciences, University of Kashmir, Srinagar, J&K, 190006, India.

Medical Oncology (Northwood, London, England)
|July 23, 2022
PubMed

Insights

This study identifies novel CDK4 inhibitors with reduced toxicity compared to palbociclib, offering potential new cancer therapies. These compounds show promise for treating various cancers where CDK4 is overexpressed.

Area of Science:

  • Oncology
  • Pharmacology
  • Computational Biology

Background:

  • Cyclin-dependent kinases (CDKs) are crucial for cell cycle regulation.
  • CDK4 overexpression is implicated in numerous cancers, leading to FDA approval of palbociclib for breast cancer.
  • Palbociclib treatment is associated with significant toxicities like anemia and neutropenia.

Purpose of the Study:

  • To screen novel CDK4 inhibitors with improved safety and efficacy profiles compared to palbociclib.
  • To investigate the therapeutic potential of these inhibitors in various CDK4-overexpressing carcinomas.
  • To analyze CDK4 expression patterns and prognostic significance across multiple cancer types.

Main Methods:

  • In silico screening using Lipinski's rule and ADMET analysis.
  • Virtual screening via molecular docking and molecular dynamics (MD) simulation.
  • Analysis of CDK4 expression and prognostic value using UALCAN, cBioportal, and KM-Plotter databases.

Main Results:

  • Identification of two novel CDK4 inhibitors demonstrating favorable pharmacokinetic properties and binding affinity.
  • Virtual screening and MD simulations confirmed the potential efficacy and stability of the selected compounds.
  • CDK4 expression analysis revealed its significant role and prognostic implications in various carcinomas.

Conclusions:

  • The novel CDK4 inhibitors show promise as safer and potentially more effective therapeutic agents than palbociclib.
  • These findings support further preclinical and clinical development of these compounds for cancer treatment.
  • Targeting CDK4 remains a viable strategy for multiple cancer types, with potential for improved patient outcomes.
Keywords:
ADMETCDK4MD simulationMolecular dockingPalbociclibPan-cancer

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.9K